We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dyne Therapeutics Inc (DYN) USD0.0001

Sell:$24.97 Buy:$25.01 Change: $0.39 (1.59%)
Market closed |  Prices as at close on 28 February 2024 | Switch to live prices |
Change: $0.39 (1.59%)
Market closed |  Prices as at close on 28 February 2024 | Switch to live prices |
Change: $0.39 (1.59%)
Market closed |  Prices as at close on 28 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dyne Therapeutics Inc. is a muscle disease company. The Company is focused on advancing therapeutics for patients with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. The Company also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Contact details

1560 Trapelo Road
United States
+1 (781) 7868230

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.93 billion
Shares in issue:
78.53 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Joshua Brumm
    President, Chief Executive Officer, Director
  • Susanna High
    Chief Operating Officer
  • Jonathan McNeill
    Senior Vice President - Business Development
  • Richard Scalzo
    Senior Vice President, Head of Finance and Administration
  • Oxana Beskrovnaya
    Chief Scientific Officer
  • Wildon Farwell
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.